{
  "url": "https://seekingalpha.com/article/4811322-relmada-therapeutics-inc-rlmd-q2-2025-earnings-call-transcript",
  "authorsByline": "SA Transcripts",
  "articleId": "58d6fd6f276a49c6b458693be0ec1250",
  "source": {
    "domain": "seekingalpha.com",
    "location": {
      "country": "us",
      "state": "NY",
      "city": "New York",
      "coordinates": {
        "lat": 40.7127281,
        "lon": -74.0060152
      }
    }
  },
  "imageUrl": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
  "country": "us",
  "language": "en",
  "pubDate": "2025-08-08T17:55:27+00:00",
  "addDate": "2025-08-08T17:58:28.703063+00:00",
  "refreshDate": "2025-08-08T17:58:28.703066+00:00",
  "score": 1.0,
  "title": "Relmada Therapeutics, Inc. (RLMD) Q2 2025 Earnings Call Transcript",
  "description": "Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ETCompany ParticipantsMaged S.",
  "content": "Good afternoon, and welcome to the Relmada Therapeutics Second Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for replay on the Relmada website.\n\nI would now like to turn the call over to Brian Ritchie from LifeSci Advisors. Please go ahead, Mr. Ritchie.\n\nThank you. Good day, everyone, and thank you for joining us today. This afternoon, Relmada issued a press release providing a business update and outlining its financial results for the 3 months ended June 30, 2025.\n\nPlease note that certain information discussed on the call today is covered under the safe harbor provision of the Private Securities Litigation Reform Act. We caution listeners that during this call, Relmada's management team will be making forward-looking statements. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business.\n\nThese forward-looking statements are qualified by the cautionary statements contained in Relmada's press release issued today and the company's SEC filings, including in the annual report on Form 10-K -- in the quarterly report on Form 10-Q for the quarter ended June 30, 2025, filed after the close today.\n\nThis conference call also contains time-sensitive information that is accurate only as of the date of this live broadcast on August 7, 2025. Relmada undertakes no obligation to revise or update any forward-looking statements to reflect events or",
  "medium": "Article",
  "links": [
    "https://seekingalpha.com/symbol/RLMD"
  ],
  "labels": [
    {
      "name": "Roundup"
    },
    {
      "name": "Opinion"
    },
    {
      "name": "Non-news"
    }
  ],
  "claim": "",
  "verdict": "",
  "keywords": [
    {
      "name": "Relmada Therapeutics",
      "weight": 0.10843339
    },
    {
      "name": "Relmada",
      "weight": 0.10029481
    },
    {
      "name": "today",
      "weight": 0.07715014
    },
    {
      "name": "certain information",
      "weight": 0.075332195
    },
    {
      "name": "Brian Ritchie",
      "weight": 0.0739943
    },
    {
      "name": "the Relmada Therapeutics Second Quarter 2025 Earnings Conference Call",
      "weight": 0.070318885
    },
    {
      "name": "Relmadas press release",
      "weight": 0.06621485
    },
    {
      "name": "Q2 2025 Earnings Call Transcript",
      "weight": 0.0653458
    },
    {
      "name": "Actual results",
      "weight": 0.06482643
    },
    {
      "name": "Good afternoon",
      "weight": 0.064399384
    }
  ],
  "topics": [
    {
      "name": "Markets"
    },
    {
      "name": "Earnings Calls"
    }
  ],
  "categories": [
    {
      "name": "Finance"
    }
  ],
  "taxonomies": [
    {
      "name": "/News/Business News/Company News",
      "score": 0.97802734375
    },
    {
      "name": "/News/Business News/Financial Markets News",
      "score": 0.97509765625
    },
    {
      "name": "/Finance/Investing/Stocks & Bonds",
      "score": 0.96044921875
    },
    {
      "name": "/Business & Industrial/Pharmaceuticals & Biotech",
      "score": 0.8603515625
    }
  ],
  "sentiment": {
    "positive": 0.14611816,
    "negative": 0.17333984,
    "neutral": 0.68066406
  },
  "summary": "Relmada Therapeutics, Inc. (RLMD) is set to discuss its second quarter 2025 earnings conference call. The company issued a press release providing a business update and outlining its financial results for the 3 months ended June 30, 2025. However, certain information discussed on the call is subject to the safe harbor provision of the Private Securities Litigation Reform Act and could lead to actual results that could differ from those stated or implied due to risks and uncertainties in the company's business. This conference call will be available for replay on the Relmada website.",
  "shortSummary": "Relmada Therapeutics' Q2 2025 earnings call will be broadcast live, featuring keynotes and cautionary statements, with potential risks and uncertainties in the event.",
  "translation": "",
  "translatedTitle": "",
  "translatedDescription": "",
  "translatedSummary": "",
  "reprint": true,
  "reprintGroupId": "b521eb37ecbd41eebcdbcc893274f5f5",
  "places": [],
  "scraped_sources": [],
  "argos_summary": "Relmada Therapeutics held its Second Quarter 2025 Earnings Conference Call, where it provided a business update and financial results for the quarter ending June 30, 2025. The call included forward-looking statements that are subject to risks and uncertainties, as outlined in the company's press release and SEC filings. The information discussed is time-sensitive and accurate only as of the call date, August 7, 2025.",
  "argos_id": "IWDKRFYDQ"
}